EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

A gut toxin that’s been linked to colorectal cancers for more than two decades may be to the sharp rise of the disease in ...

Dr. Mickey Mehta warns that bread could be harmful if eaten regularly and advises people to reduce intake. Though ABS is rare, it is often underdiagnosed and may affect people with gut imbalances or ...

The pharmaceutical company said Tuesday that the drug will be able to be used against urinary tract infections caused by the microorganisms Escherichia coli, Klebsiella pneumoniae, Citrobacter ...

The drug is effective against UTIs caused by E. coli, klebsiella, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. The most common side effects reported from using the ...

coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus or Enterococcus faecalis in women 12 years of age and older. These types of UTIs are the most common ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc SAVA nosedived following the failure of a late-stage study, while ...

Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle ...

In trials, the drug was effective against common UTI-causing bacteria, including Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

coli, Klebsiella pneumoniae, Citrobacter freundii complex, Enterococcus faecalis, and a type of staph infection known as Staphylococcus saprophyticus. “The approval of Blujepa is a crucial ...

Blujepa, a first-in-class oral antibiotic, is approved for treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus ...